Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Stemline IND gains acceptance by FDA
May 2014
SHARING OPTIONS:

NEW YORK—The U.S. Food and Drug Administration has accepted Stemline Therapeutics Inc.’s Investigational New Drug (IND) application for SL-701, the company reported recently. This acceptance will allow Stemline to move the compound into a Phase 2 trial of adults with glioblastoma multiforme in first recurrence. SL-701 is a subcutaneously administered cancer vaccine consisting of multiple synthetic peptides designed for increased immunoreactivity against targets overexpressed on the cancer stem cells and tumor bulk of gliomas. The compound is based on a vaccine developed at the University of Pittsburgh. Stemline’s Phase 2 trial will be a multicenter study of 80 to 100 patients that will seek to evaluate SL-701 in adults with glioblastoma multiforme that has recurred following initial treatment with surgery, radiation and chemotherapy, with co-primary endpoints of overall response rate and survival.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.